Korean biotech firm Genexine announced Friday that the company has submitted a biologics license application to the country's Ministry of Food and Drug Safety for the company’s anemia ...

To comprehend the risks involved with third party IP and freedom to operate, let’s consider how the approved drug Mircera® was excluded from the market for seven years after being approved by ...

DaVita (DVA -1.55%) Q1 2023 Earnings Call May 08, 2023, 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good evening. My name is Michelle ...

The investigational chronic kidney disease drug candidate matched Roche and CSL Vifor’s Mircera in an interim look at phase 3 data.

It is aimed to confirm non-inferiority by administering and comparing with Roche's Mircera, a third-generation long-acting anemia treatment.

SEOUL, South Korea-- (BUSINESS WIRE)--A clinical-staged proprietary platform technology biotech company Genexine (KQ 095700, CEO Neil Warma) and its Asian regional partner, KG Bio unveiled the interim ...

Vadadustat demonstrated noninferiority to a long-acting ESA for the maintenance treatment of anemia due to CKD in hemodialysis patients.

CSL investors have been waiting since December to hear what it plans to do with the Swiss renal thereby and iron deficiency company it bought last year.

CSL shares dipped below $300 on Friday - their lowest in more than four weeks - after the biotech giant confirmed it is in talks with an unidentified offshore party.

According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity ...

The FDA approved Mircera for the treatment of pediatric patients 5 to 17 years of age on hemodialysis who are converting from another erythropoiesis-stimulating agent after their hemoglobin level ...